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ABSTRACT
Headaches are the sixth leading cause of disability worldwide, and the
third leading cause of disability amongst those aged 50 and older. Several
headache disorders, including migraines, have been associated with nitric oxide
production. It is widely accepted that the pain associated with headache
disorders is due to the ability of nitric oxide to function as a vasodilator. While
nitric oxide is a known vasodilator and has been linked to headache disorder, it is
also produced in response to bacterial infections. Periodontal disease is the
result of long term bacterial infections occurring in the gum line and nitric oxide is
produced in response. Because periodontal disease incites the production of
nitric oxide, it is biologically plausible that periodontal disease could be
associated with headache disorders.
To investigate the relationship between periodontal disease and headache
disorders, bivariate and ordinal logistic regressions were employed while
controlling for age, education, income, physical activity level, smoking status,
body mass index, and diet. The population consisted of 1206, postmenopausal
women from the Women’s Health Initiative.
While our study reports no significant association between periodontal
disease and headache disorders, our study did provide evidence of a link
between Porphyromonas gingivalis, an important microbe in periodontal disease
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pathogenesis capable of inducing nitric oxide production, and migraines (Odds
ratio = 2.252; 95% Confidence interval: 1.121 to 4.526).
P. gingivalis presence is positively associated with migraines among older
white women after controlling for potential confounders. Further investigation into
measures of oral health, oral microbes, and NO in relation to headache disorders
is warranted.
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CHAPTER 1
INTRODUCTION
1.1 BACKGROUND:
According to the Global Burden of Disease Survey released in 2010,
(GBD2010), headaches are the 6th leading cause of disability worldwide, and the
3rd leading cause of disability amongst those aged 50 and older (Stephen S
Lim‡, Theo Vos, Abraham D Flaxman, Goodarz Danaei et al., 2012). These
findings illustrate the large impact headache disorders have on individuals and
society, consequently, as a response, many organizations and alliances were
established (Steiner, Stovner, & Birbeck, 2013). For example, the World
Headache Alliance (WHA), a coalition of over 40 organizations formed with the
aim “to reduce the burden of headache disorders throughout the world via
sharing information among headache organizations and by increasing the
awareness and understanding of headaches as a public health concern with
profound social and economic impact” (WHA, 2017). Acknowledgement of the
global burden experienced from headache disorders has called for more work in
understanding all aspects of these disorders (Steiner et al., 2013), as a better
understanding of factors that trigger headaches can help in prevention and
reduce related disability.
One such study recently reported the possibility of a symbiotic relationship
between oral commensal bacteria and humans through the salivary nitrate-nitrite-
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nitric oxide pathway that could provoke migraines (Gonzalez et al., 2016). That
study proposed that the symbiotic relationship between commensal, oral bacteria
and salivary enzymes helps reduce nitrates ingested to nitric oxide (NO), which
has been implicated in the pathophysiology of most headache disorders,
including migraines, tension type headaches, and cluster headaches (D’andrea
et al., 1994; Gruber et al., 2010; Olesen, 2008; Sarchielli et al., 1996;
Shimomura, Murakami, Kotani, Ikawa, & Kono, 1999). Migraine pain felt in the
temporomandibular, facial, and maxillary areas has been attributed to vascular
dilatation (Tietien, 2009), and NO is an effective vasodilator. Because of NO’s
ability as a vasodilator, it is widely accepted that NO causes the pain suffered
from migraines via the nociceptor activation resulting from the vascular dilatation
of the dural and meningeal blood vessels (Schürk et. al., 2009). Consequently,
nitrates, a precursor to NO, are commonly used as cardiac therapeutics (Thadani
& Rodgers, 2006), with headaches being a common side effect of prescription
nitrates (Bagdy, Riba, Kecskeméti, Chase, & Juhász, 2010). Furthermore,
obstruction of nitric oxide synthases (NOS) has been shown to attenuate
migraines without aura, tension-type headaches, and cluster headaches (Olesen,
2010).
The findings reported by Gonzalez and colleagues are the first
contribution to headache etiology research suggesting oral microorganisms as
the cause of headaches linked to NO (Gonzalez et al., 2016). The NIH funded
OsteoPerio ancillary study of the Woman’s Health Initiative (WHI) has collected
data on oral microbial species identified in 1,256 postmenopausal women from
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Buffalo, New York. Data from this study will allow us to further investigate the
effect of oral microbes on headache disorders, however I propose a different
causal pathway than Gonzalez and colleagues. I propose that bacterial infections
associated with periodontal disease induce an inflammatory response,
specifically the production of NO, that contributes to the vasodilation and
subsequent pain suffered in headache disorders.
Periodontal diseases are chronic inflammatory infections associated with
gram-negative bacteria (Slade, Offenbacher, Beck, Heiss, & Pankow, 2000).
Severe periodontal disease slowly destroys the supporting tooth structures
consisting of the gums and bone. Clinically, periodontal disease is classified
based on the degree to which the supporting tooth structures are damaged. In
addition to being a vasodilator, NO is also an oxidant and is produced by the
immune system in response to bacterial infections (Mancinelli & McKay, 1983).
The lipopolysaccharides (LPS) of several gram-negative bacteria (Eun Young
Choi et al., 2011; Kim, Ha, Choi, Choi, & Choi, 2004; Pelt, Zimmermann, Ulbrich,
& Bernimoulin, 2002; Skaleric, Gaspirc, McCartney-Francis, Masera, & Wahl,
2006; Hussain, Mckay, Gonzales-Marin, & Allaker, 2015; E. Y. Choi et al., 2007;
Herath et al., 2016; Kato, Mikami, & Saito, 2001; Velsko et al., 2015; Chukkapalli
et al., 2015) and the lipoteichoic acids of a gram-positive bacteria associated with
periodontal disease have been shown, in vivo, to stimulate NO production by the
immune system (English, Patrick, Orlicek, McCordic, & Shenep, 1996; Jian Jun
Gao, Xue, Zuvanich, Haghi, & Morrison, 2001). Moreover, there is evidence of
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increased NO production in inflamed, human gingival tissue (Kendall, Haase, Li,
Xiao, & Bartold, 2000; Hirose et al. 2001).
While there is limited literature on the association between periodontal
disease and headache disorders, there is plausible biological evidence
supporting a causal link. The NO produced in response to periodontal disease
could be triggering the pain suffered from headache disorders via vasodilation in
the brain.
1.2 PURPOSE & SPECIFIC AIMS:
Aim 1: Assess the relationship between periodontal disease and headache
disorders.
Hypothesis 1a: Severe or moderate periodontal disease, as defined by the
Centers for Disease Control and Prevention (CDC) and American
Academy of Periodontology (AAP), is positively associated with headache
disorders compared with mild or no periodontal disease.
Hypothesis 1b: Increasing mean Clinical Attachment Level (CAL) is
positively associated with headache disorders.
Aim 2: Assess the relationship between NO-production inducing bacteria and
headache disorders.
Hypothesis 2a: Infection with bacteria in the dental plaque clinically shown
to induce NO-production (model species: Streptococcus sanguis,
Prevotella intermedia, Campylobacter rectus, Porphyromonas gingivalis,
Fusobacterium nucleatum. and Tannerella forsythensis) is associated with
headache disorders.
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Hypothesis 2b: Infection with bacteria in the dental plague not clinically
shown to induce NO-production (model species: Capnocytophaga spp.,
and Eubacterium saburreum) is not associated with headaches.
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CHAPTER 2
LITERATURE REVIEW
2.1 SEARCH METHODS:
A literature search was conducted via PubMed to locate studies evaluating
the association between periodontal disease and headache disorders. Advanced
search criteria limited the search results to studies published in the English
language and performed on human subjects. No limits were set for publication
date. I included the following search terms: (“headache” OR “migraine” OR
“headache disorder” OR “migraine disorder” OR “cluster headache” OR “tensiontype headache”) AND ("periodontal disease” OR "gingival disease” OR "gum
disease” OR “periodontal disease" OR "gingivitis"). The PubMed search
produced 28 articles and one additional article identified later, whose titles and
abstracts were reviewed. Of those, six articles were read in their entirety to
screen for inclusion. To be eligible for inclusion, the study had to assess the
relationship between periodontal disease and any headache disorder. Because
of the limited literature on this association, I also included pertinent case studies.
Only one article assessed the relationship between periodontal disease and a
headache disorder in an epidemiological study. Figure 2.1 is a flowchart of the
literature review search.
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2.2 FINDINGS:
Two studies (Table 2.1) were included in the literature review; one was a
case-control study (Peskersoy, Peker, Kaya, Unalp, & Gokay, 2016) and the
other a case report (Hoffman & McCulloch, 2013). Both studies had confirmed
cases of oral health status via a dentist administered clinical assessment.
2.3 DISCUSSION:
The literature assessing the relationship between periodontal disease and
headache disorders is extremely limited. Our literature search produced a single
epidemiological study and one case report. Peşkersoy and colleagues recently
published the results of their multi-center, parallel, case-controlled clinical study
assessing the relationship between migraine disorders and oral comorbidities.
They found that tooth wear and abrasion were more frequent in patients with
migraines (76%, P < 0.05). Furthermore, the mean number of decayed, missing
or filled teeth (DMFT) (mean 3.79 vs. 2.71, P < 0.05) and gingival plaque index
scores (mean 1.64 vs. 1.23, P < 0.05) showed significant differences between
those with and without migraines (Peskersoy et al., 2016). However, they
proposed that the oral comorbidities were the result of their migraine disorder
and not vice versa, yet this case-controlled study did not establish temporality
thus limiting the ability to determine causality. The study does, however, provide
evidence of an association between oral health status and headache disorders
that warrants further examination.
Furthermore, the case report found in our literature review was on a 60year-old man with a 7-year history of cluster headaches. The patient sought
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treatment from an oral surgeon for pain in the left upper second molar ipsilateral
upon which the doctor discovered severe infection, decay, and inflammation
while extracting the tooth. Removal of the infected tooth resulted in the
attenuation of his cluster headaches. However, the authors propose that nerve
involvement was the cause of the cluster headaches (Hoffman & McCulloch,
2013). No measures or rankings of periodontal disease were reported for this
case report.
2.4 FUTURE DIRECTIONS:
Future studies investigating the etiology of headache disorders should
focus on oral comorbidities. While the literature investigating the relationship
between periodontal disease and headache disorders is limited, the clinical
evidence supports the biological plausibility outlined in the background.
Therefore, my investigation into the relationship between periodontal disease and
headache disorders would contribute to the limited existing literature.
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Figure 2.1: Flowchart of literature review
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Table 2.1: Epidemiological and clinical studies investigating the association between periodontal disease and
headache disorders
First author,
year(s), place
Peskersoy et
al. 2016,
Turkey

Measure of
periodontal
disease
DMFT and
gingival
plaque index

Outcome
variable(s)

Control
variables

Main findings

Migraine

Tooth wear and abrasion was
more frequent in patients with
migraine (76%, P < 0.05).
Furthermore, the DMFT scores
(mean 3.79 vs. 2.71, P < 0.05)
and gingival plaque index
scores (mean 1.64 vs. 1.23, P <
0.05) showed significant
differences between the groups.

Case report

Physician
inspection
revealed signs
of decay and
periodontitis.
No official
diagnosis for
periodontal
disease was
stated. No
measures of
periodontal
disease were
reported.

Cluster
headache

Adjustment was
made for
individual’s sex,
age, systemic
conditions,
existence of
comorbidities,
and overall
dental health
and care status.
N/A
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Study
design and
sample size
Case-control,
n=2001

Hoffman &
McCullough
2013, USA

“A 60-year-old man with a 7year history of cluster
headaches was seen by an oral
surgeon for evaluation of pain in
the left upper second molar
ipsilateral to the side affected by
the headaches. During
extraction of the tooth, infection,
decay, and inflammation were
discovered. Since the extraction
in November 2008, the patient
has experienced one episode of
cluster headaches as of April
2013.”

CHAPTER 3
METHODS
3.1 STUDY POPULATION:
Participants were recruited from the WHI OS, during their year 3 visit, to
participate in the Buffalo Osteoporosis and Periodontal Disease Study
(OsteoPerio Study), an ancillary study of the Women’s Health Initiative (WHI)
Observational Study (OS) seeking to “examine the association between
osteoporosis, oral bone loss, and periodontal disease in a well-characterized
cohort of postmenopausal women” (Sahli et al., 2015). The OsteoPerio study has
previously been reviewed and approved by the Health Sciences Institutional
Review Board at the University at Buffalo, and all participants provided signed
informed consent. Participants were offered an incentive of a free bone density
scan and an oral examination (Brennan et al., 2007). Procedures for study
recruitment, retention, and data collection have been previously described
(Wactawski-Wende et al., 2005; Brennan et al., 2007; Sahli et al., 2015). My
study population is comprised of 1,206 female participants; the population was
reduced from 1,256, as participants with missing values for all exposures and
outcomes of interest were excluded.
3.2 EXPOSURE OF INTEREST FOR AIM I:
Participants were offered free oral exams as incentive for participation in
the OsteoPerio ancillary study. This occurred during their year three clinical
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assessment. This included assessing the presence of decaying or filled teeth and
accounting for each missing tooth via self-report and several measures of
periodontal disease were taken. Moreover, samples of subgingival plaque were
taken from each participant (Brennan et al., 2007). Pocket depth (PD) and mean
Clinical Attachment Level (CAL) were two of the measures used to classify
participants’ severity of periodontal disease. PD is a measure of the distance
from the gingival margin to the bottom of the pocket and is a useful measure of
periodontal disease. Similarly, CAL is a measure of the distance from the
cement-enamel junction to the bottom of the pocket (American Academy of
Periodontology, 2015).
To address the first hypothesis of Aim 1, participants were classified as
having no or mild, moderate, or severe periodontal disease based on the CDC
and AAP rankings (Page & Eke, 2007), and recorded as 0, 1, or 2, respectively.
Mild periodontal disease was defined as have two or more interdental sites with
pocket depth (PD) ≥ 4 mm and two or more interdental sites with CAL ≥ 3 mm or
having PD ≥ 5 mm on any tooth. Moderate periodontal disease was defined as
having two or more interdental sites on different teeth with CAL ≥ 4 mm or having
PD ≥ 5 mm on more than one interdental site on different teeth. Severe
periodontal disease was classified as having one or more interdental sites with
PD ≥ 5 mm and two or more interdental sites with CAL ≥ 6 mm (Page & Eke,
2007).
Additionally, information gathered from the oral examination was used
calculate a mean CAL for each participant. To make comparisons between
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various levels of mean CAL, participants were divided into four groups, the
quartiles of mean CAL. Quartile 1 (Q1) is comprised of participants with a mean
CAL less than or equal to 1.95. Quartile 2 (Q2) is comprised of participants with a
mean CAL greater than 1.95 and less than or equal to 2.27. Quartile 3 (Q3) is
comprised of participants with a mean CAL greater than 2.27 and less than or
equal to 2.66. Lastly, Quartile 4 (Q4) is comprised of participants with a mean
CAL greater than 2.66. Additionally, mean CAL was divided into quartiles within
all logistic regression models.
3.3 EXPOSURE OF INTEREST FOR AIM II:
As part of the oral examination received by participants in OsteoPerio
ancillary study, subgingival plaque samples were taken via the paper point
technique (Brennan et al., 2007). Samples were taken from up to 12 teeth
previously dried with cotton to reduce contamination. The following species were
selected for this study and detected via immunofluorescence: Streptococcus
sanguis, Prevotella intermedia, Campylobacter rectus, Porphyromonas gingivalis,
Fusobacterium nucleatum. Tannerella forsythensis, Capnocytophaga spp., and
Eubacterium saburreum. Methods have been previously described in detail
(Brennan et al., 2007).
For this study, the bacterial species were divided into two groups. A
literature search was conducted for clinical evidence of inducing NO production
for each of the targeted bacterial species. Results from the search are recorded
in Table 3.1. Group 1 consists of bacterial species that may induce NO
production, as supported by literature, and Group 2 consists of the remaining
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bacterial species not known to induce NO production. Group 1 includes S.
sanguis, P. intermedia, C. rectus, P. gingivalis, F. nucleatum, and T. forsythensis.
Group 2 includes the remaining species as there is no literature reporting the
ability of Capnocytophaga spp. or E. saburreum to induce NO production. All
species were recoded as either present (1) or absent (0); therefore, an additional
variable “Infection” was created to illustrate the number of Group 1 bacteria
identified in each participant. All participants who were infected with two or less
Group 1 bacteria were considered to have no or mild infection. Participants who
were infected with three or four Group 1 bacteria were considered to have
moderate infection; and participants who were infected with five or six Group 1
bacteria were considered to have severe infection.
3.4 OUTCOMES OF INTEREST:
3.4.1 Migraines
During their baseline visit for the WHI OS, participants were asked “Has a
doctor told you that you have any of the following conditions or have you had any
of the following procedures?” and were provided a list that included migraine
headaches. Participants responses were coded as absent (0) or present (1).
Because the presence of migraines was recorded as absent or present, with no
information about type of migraine, bivariate logistic regression was used for all
models assessing the relationship between migraines and our exposures of
interest.
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3.4.2 Headaches
During their third-year visit, participants were given a list of symptoms, one
of which being headaches or migraines, and asked “for each item, mark the
one… [response] that best describes how bothersome the symptom was during
the past 4 weeks for you”. The options were “Symptom did not occur”, “Symptom
was mild” defined as symptom did not interfere with usual activities, “Symptom
was moderate” defined as symptom interfered somewhat with usual activities, or
“Symptom was severe” defined as symptom was so bothersome that usual
activities could not be performed. The response to this question was used as an
indicator of the presence of any headache disorder, and because the response
was recorded ordinally, ordinal or cumulative logistic regression was
implemented in all models examining the relationship between our exposures of
interest and headache disorders.
3.5 POTENTIAL CONFOUNDERS:
The following variables were identified as potential confounders via a
literature search: age, education, income, race, body mass index (BMI), anxiety,
depression, smoking, physical activity, cholesterol, medication use, blood
pressure, and eating behaviors (Aamodt, Stovner, Midthjell, Hagen, & Zwart,
2007; Bond, Roth, Nash, & Wing, 2011; Buse, Silberstein, Manack,
Papapetropoulos, & Lipton, 2013; Cappy, Lucas, Catteau-Jonard, & Robin, 2015;
Fagernæs et al., 2015; Heckman & Britton, 2015; Martin & Vij, 2016; Stovner et
al., 2007; Thadani & Rodgers, 2006; Varkey, Hagen, Zwart, & Linde, 2008;
Younger, 2016). However, data collected on cholesterol were too incomplete to

15

include in the analysis and the population was mostly white (97.4%) thus race
was also excluded from the analysis. The remaining potential confounders were
controlled for in each model to create the most theoretically based model. Refer
to Figure 3.1, a Directed Acyclic Graph (DAG) illustrating the association
between periodontal disease and headache disorders and the previously
mentioned potential confounders. Additionally, Table 3.2 lists each variable
treated as a potential confounder when building the model, literature justifying
why the variable was considered a confounder, and how the variable was
recorded.
3.6 STATISTICAL ANALYSIS:
3.6.1 Demographic differences
Participants were ranked by periodontal disease status as defined by the
CDC and AAP. Comparisons were made between those with no or mild
periodontal disease versus those with moderate or severe periodontal disease.
Differences in continuous variables are recorded as the mean and standard
deviation (SD) and assessed via the Student t test. Categorical variables were
assessed via the Pearson Chi-square test or the Fischer’s Exact test when
appropriate.
Similarly, differences between participants at the four quartiles of mean
CAL are recorded in Table 5. Comparisons were made between Q1, Q2, Q3, and
Q4 of mean CAL. Differences in continuous variables are recorded as the mean
and standard deviation (SD) and assessed via the one-way ANOVA test.
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Categorical variables were assessed via the Pearson Chi-square test or the
Fischer’s Exact test when appropriate.
Furthermore, comparisons were made between those with no or mild,
moderate, or severe Group 1 bacterial infections. Differences in continuous
variables are recorded as the mean and standard deviation (SD) and assessed
via one-way ANOVA test. Categorical variables were assessed via the Pearson
Chi-square test or the Fischer’s Exact test when appropriate.
Lastly, comparisons were made between the participants with no, one, or
two Group 2 bacteria present. Differences in continuous variables are recorded
as the mean and standard deviation (SD) and assessed via the one-way ANOVA
test. Categorical variables were assessed via the Pearson Chi-square test or the
Fischer’s Exact test when appropriate.
3.6.2 Models
3.6.2.1 Migraines
To address the hypotheses stated in Aim 1, periodontal disease status
was defined two ways, by CDC/AAP rankings and by mean CAL quartiles. To
address Hypothesis 1a, bivariate logistic regression was implemented to
determine the odds of having suffered migraines for those with moderate or
severe periodontal disease compared to those with no or mild periodontal
disease while controlling for age at enrollment, history of using birth control,
cardiac therapeutic usage, caffeine intake in mg, and alcohol servings per week.
Furthermore, an additional bivariate logistic regression was used to determine
the odds of having suffered migraines for those with mean CAL in quartile 2, 3,
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and 4 compared to quartile 1 to address Hypothesis 1b. Similarly, this model also
controlled for age at enrollment, history of using birth control, cardiac therapeutic
usage, caffeine intake in mg, and alcohol servings per week.
To address both hypotheses stated in Aim 2, a final bivariate logistic
regression model was employed to determine the odds of having suffered a
migraine for those with moderate or severe infection of Group 1 bacteria
compared to those with no or mild infection of Group 1 bacteria while controlling
for the presence or absence of Group 2 bacteria, age at enrollment, history of
using birth control, cardiac therapeutic usage, caffeine intake in mg, and alcohol
servings per week. It is necessary to control for the presence of Group 2 bacteria
within the model assessing the relationship between Group 1 bacteria and
migraines; therefore, we only need the single model to address both hypotheses
from Aim 2. Additional bivariate logistic regression models were used to assess
the relationship between each Group 1 bacterial species and migraines. All six
models controlled for age at enrollment, history of using birth control, cardiac
therapeutic usage, caffeine intake in mg, and alcohol servings per week.
3.6.2.2 Headache disorders
Methods for assessing the odds of having suffered a headache disorder
for each hypothesis are like the previously mentioned methods for assessing the
odds of having suffered a migraine, with a few exceptions. Because participants
were asked if they had suffered no or mild, moderate, or severe pain, ordinal
regression was employed to determine the odds of having suffered a headache
disorder for all exposures. All models controlled for age at enrollment, history of
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using birth control, cardiac therapeutic usage, blood pressure, and alcohol
servings per week.
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Figure 3.1: Directed Acyclic Graph (DAG) of the association between periodontal
disease and headache disorders
a. Sources: Katz et al., 2002
b. Sources: Mirowsky & Ross, 1992; Jorm, 2000; Twenge, 2000; Stevens et
al., 1998; Franklin et al., 1997; Schaefer et al., 1994
c. Sources: Leite et al. ,2017; Bodnar et al., 2017; Green & Benzeval,d
2013; Wardle & Steptoe, 2003; Hagen et al., 2002; Martikainen & Marmot
2017; Colhoun, Hemingway, & Poulter 1998; Winkleby, et al. 1998
d. Sources: Aamodt, Stovner, Midthjell, Hagen, & Zwart, 2007; Primatesta et
al., 2001; Gepner et al., 2011; Tomar & Asma, 2000
e. Sources: Varkey, Hagen, Zwart, & Linde, 2008; Stefanick et al., 1998;
Cornelissen & Smart, 2013; WHO 2013; Bawadi et al., 2011
f. Sources: Fagernæs et al., 2015; Prospective Studies Collaboration, 2007
g. Sources: Bond, Roth, Nash, & Wing, 2011; Brown et al., 2000; Faheem et
al., 2010
h. Sources: Thadani & Rodgers, 2006; Cappy, Lucas, Catteau-Jonard, &
Robin, 2015
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Table 3.1 Group 1 and Group 2 bacterial species
Bacteria spp. and
Support
characteristics
Group 1: NO production inducting bacteria
Streptococcus sanguis While periodontal disease is typically associated
with gram-negative bacteria, the lipoteichoic
acids from S. sanguis has been shown to
stimulate NO production from murine and
C3H/HeJ macrophages (English, Patrick, Orlicek,
McCordic, & Shenep, 1996; Jian Jun Gao, Xue,
Zuvanich, Haghi, & Morrison, 2001).
Prevotella intermedia
P. intermedia lipopolysaccharide (LPS) has been
shown to stimulate the release of NO (Eun Young
Choi et al., 2011; Kim, Ha, Choi, Choi, & Choi,
2004; Pelt, Zimmermann, Ulbrich, & Bernimoulin,
2002; Skaleric, Gaspirc, McCartney-Francis,
Masera, & Wahl, 2006)
Campylobacter rectus
C. rectus LPS has been shown to induce NO
production in oral keratinocytes (Hussain, Mckay,
Gonzales-Marin, & Allaker, 2015)
Porphyromonas
P. gingivalis lipid A-associated proteins and LPS
gingivalis
can induce nitric oxide production (E. Y. Choi et
al., 2007; Herath et al., 2016).
Fusobacterium
Live F. nucleatum can induce NO production in
nucleatum
murine macrophages (Kato, Mikami, & Saito,
2001).
Tannerella forsythensis There is evidence that a polymicrobial consortium
(formally known as T. including Tannerella forsythia was shown to
forsythia)
increase NO production (Velsko et al., 2015).
However, there are conflicting reports on
whether T. forsthensis induces NO
production (Chukkapalli et al., 2015).
Group 2: Control bacteria not considered to induce NO production
Capnocytophaga spp.
No evidence of inducing NO production
Eubacterium
No evidence of inducing NO production
saburreum
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Table 3.2: Potential confounders for the association between periodontal
disease and headache disorders
Variable
Age at baseline

Justification
Will include to control for age as a potential confounder
and to prevent any age affects.
Education
When defining SES by educational level or type of
occupation, low status was associated with increased
risk of frequent and chronic headache at follow-up.
(Hagen et al., 2002)
Income
Previous studies found that risk of headache decreased
with increasing income, but only among men (Hagen et
al., 2002). It’s still important to see how income affects
headaches in this exclusively female population.
BMI
Evidence indicates a possible link between migraine and
obesity, with the latter either exacerbating headache
activity in people currently suffering from migraine or
possibly increasing the risk for having migraine. (Bond et
al., 2011)
Depression
Migraine is comorbid with several psychiatric disorders,
variable
including depression, anxiety disorders, and PTSD.
(Buse et al., 2013)
Smoking
Passive smoking was associated with higher headache
prevalence. (Aamodt et al., 2007)
Physical Activity A study reported that individuals reporting headaches
were typically less active (Varkey et al., 2008).
Medication use: Nitrates are effective cardiac agents; however
Cardiac
headaches are the most common consequence (Thadani
therapeutics
& Rodgers, 2006).
Medication use: Oral contraceptives have been associated with migraine
Oral
disorders (Cappy et al., 2015).
contraceptive
Blood pressure Two large-scale population-based cohort studies,
HUNT2 and HUNT3 reported an inverse association
between blood pressure and headaches (Fagernæs et
al., 2015).
Dietary intake:
Caffeine withdrawal has been reported to trigger
Caffeine
headaches (Martin & Vij, 2016).
Headaches are associated with alcohol overuse (Aamodt
et al., 2007) (Martin & Vij, 2016).
Caffeine withdrawal have the strongest evidence for
triggering attacks of headache (Martin & Vij, 2016)
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CHAPTER 4
RESULTS
4.1 POPULATION DEMOGRAPHICS:
Population characteristics are shown in Tables 4.1-10. Table 4.1 displays
our population characteristics by each exposure level that addresses our
hypotheses. The majority of the study population suffers from periodontal
disease with 16.25% suffering from severe periodontal disease and 57.05%
suffering from moderate periodontal disease. Most participants (51.49%), were
infected with one or two Group 1 bacteria, and no Group 2 bacteria (50.58%).
Results are shown in Table 4.
As shown in Tables 4.2 and 4.3, differences between participants with
moderate or severe periodontal disease were older, more likely to be former or
current smokers, were less physically active, and were more likely to be infected
with P. intermedia, T. forsythensis, E. saburreum, C. rectus, and P. gingivalis
than participants with no or mild periodontal disease. No statistically significant
differences were observed between participants with moderate or severe
periodontal disease versus participants with no or mild periodontal disease with
regards to BMI, history of birth control usage, cardiac therapeutic usage, diastolic
blood pressure, caffeine intake, alcohol servings per week, and the presence of
S. sanguis, Capnocytophaga spp. or F. nucleatum.
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Differences between the quartiles of mean CAL are also found in Tables
4.4-4.6. Participants in the fourth quartile are older, more likely to be current
smokers, less physically active, and are more likely to be infected with P.
intermedia, T. forsythensis, E. saburreum, C. rectus, and P. gingivalis.
Additionally, participants in the third and fourth quartiles drank more caffeine than
participants in the first and second quartiles. No significant differences were seen
between the four quartiles in regard to total family income, education, BMI,
history of birth control usage, cardia therapeutic usage, diastolic blood pressure,
alcohol servings per week, or infection with S. sanguis, Capnocytophaga sp., and
F. nucleatum.
As see in Tables 4.7 and 4.8, participants with severe infections of Group
1 bacteria were more likely to be overweight, less likely to be current smokers,
drank more caffeine, and were more likely to be about of the fourth quartile of
Mean CAL. Similarly, participants with more severe Group 2 infections were also
more likely to be overweight (Tables 4.9-4.10). Differences between the varying
degrees of infections for Group 1 and Group 2 bacteria are recorded in Table 6.
4.2 MODEL RESULTS:
4.2.1 Migraines
Results from crude and adjusted models assessing the specific aims and
all hypotheses for migraines is displayed in Table 4.11. To address Aim 1,
bivariate logistic regression models were implemented to assess the relationship
between periodontal disease and migraines; periodontal disease was defined two
ways, by CDC/AAP rankings and by Mean CAL. Severe or moderate periodontal
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disease defined by CDC/AAP rankings was not associated with migraines in both
unadjusted (OR = 0.812, 95% CI: 0.544, 1.213) and adjusted (OR = 0.811, 95%
CI: 0.530, 1.241) models. Similarly, periodontal disease classified by quartiles of
Mean CAL was not associated with migraines in both unadjusted and adjusted
models when comparing the second and third quartiles to the first quartile. The
unadjusted and adjusted OR for participants in the second quartile of Mean CAL
was 1.109, 95% CI: 0.673, 1.827 and 1.071, 95% CI: 0.628, 1.828, respectively.
When comparing participants in the third quartile of Mean CAL to participants in
the first quartile of Mean CAL, the odds of suffering from a migraine were 1.746,
95% CI: 1.000, 3.048 in the crude model and 1.638, 95% CI: 0.904, 2.966, in the
adjusted model. However, for participants in the fourth quartile, the unadjusted
association between Mean CAL was not associated with migraines in the crude
(unadjusted OR = 1.065, 95% CI 0.648, 1.749) or adjusted models (adjusted OR
= 0.930, 95% CI: 0.546, 1.584). Both adjusted models controlled for age,
education, income, BMI, smoking status, physical activity, history of birth control,
cardiac therapeutic usage, diastolic blood pressure, alcohol consumption, and
caffeine consumption.
To address hypotheses from Aim 2, a bivariate logistic regression model
was implemented to assess the relationship between Group 1 and 2 bacteria and
migraines. The adjusted model controlled for all the above-mentioned covariates.
The relationship between Group 1 bacterial species and migraines was assessed
two ways, via an infection ranking and by assessing the relationship between the
presence of each individual bacterial species. More information on the bacterial

25

species of interest and the infection ranking is in section 3.3. Moderate and
severe infection with Group 1 bacteria approached positive associations with
migraines in unadjusted and adjusted models, but did not reach statistical
significance. Participants with moderate infection compared to those with no or
mild infection had an unadjusted OR of 1.622, 95% CI: 0.992, 2.652 and adjusted
OR 1.511, 95% CI: 0.879, 2.599. Also, participants with severe infection
compared to those with no or mild infection have unadjusted OR 1.589, 95% CI:
0.673, 3.754 and adjusted OR 1.293, 95% CI: 0.508, 3.288. The presence of P.
gingivalis was positively associated with migraines in unadjusted (OR = 2.109,
95% CI: 1.082, 4.110), and adjusted (OR = 2.252, 95% CI: 1.121, 4.526) models.
Other individual Group 1 bacterial species were not associated with migraines.
Infection with one or two Group 2 bacteria, the control bacteria, were not
associated with migraines. The odds of suffering from migraines for those with a
single infection of Group 2 bacteria was 0.821, 95% CI: 0.545, 1.236 in the
unadjusted model and 0.776, 95% CI: 0.498, 1.207 in the adjusted model.
Infection with two Group 2 bacteria resulted in an unadjusted OR of 1.455, 95%
CI: 0.852, 2.484 and adjusted OR of 1.363, 95% CI: 0.756, 2.458. Both Group 2
bacterial species, Capnocytophaga sp. and E. saburreum, were positively, yet
insignificantly associated with migraines in crude and adjusted analyses.
4.2.2 Headaches
Similar analyses were performed to also assess the relationship between
our exposures and headache disorders; however, the variable for headache
disorders was recorded as an ordinal variable with four options. As such, ordinal
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logistic regression was implemented and results for all crude and adjusted
models related to headache disorders were recorded in Tables 4.12-4.14. The
odds of suffering from mild, moderate, and severe headache symptoms are
recorded in Tables 4.12, 4.13, and 4.14, respectively. From these data, we must
conclude that periodontal disease was not associated with headaches. Severe or
moderate periodontal disease as defined by the CDC/AAP rankings was not
significantly associated with any level of headache pain. For participants
suffering from moderate or severe periodontal disease, the odds of suffering mild
headache symptoms were 0.865, 95% CI: 0.699, 1.119 in the crude model and
0.758, 95% CI: 0.336,1.667 in the adjusted model. For participants suffering from
moderate or severe periodontal disease the odds of suffering from moderate
headache symptoms was 0.737, 95% CI: 0.497,1.091 in the crude model and
0.728, 95% CI: 0.483,1.098 in the adjusted model. For participants suffering from
moderate or severe periodontal disease the odds of suffering from severe
headache symptoms was 0.768, 95% CI: 0.358,1.650 in the unadjusted model
and 0.758, 95% CI: 0.336, 1.710 in the adjusted model. The adjusted model
controlled for age, education, income, BMI, smoking status, physical activity,
history of birth control, cardiac therapeutic usage, diastolic blood pressure,
alcohol consumption, and caffeine consumption.
To address Hypothesis 2 from Aim 1, ordinal logistic regression was
implemented to assess the relationship between mean CAL and suffering various
levels of headache pain. Again, our data suggests no relationship between
periodontal disease and headaches. For participants in the second quartile of
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Mean CAL, the odds of suffering from mild headache symptoms was 1.015, 95%
CI: 0.735, 1.402 in the unadjusted model and 0.986, 95% CI: 0.701,1.387 in the
adjusted model. For participants in the third quartile of Mean CAL, the odds of
suffering from moderate headache symptoms was 0.699, 95% CI: 0.402,1.112 in
the unadjusted model and 0.614, 95% CI: 0.356,1.059 in the adjusted model.
Lastly, for participants in the fourth quartile of Mean CAL, the odds of suffering
from severe headache symptoms was 0.518, 95% CI: 0.189,1.419 in the
unadjusted model and 0.510, 95% CI: 0.168,1.544 in the adjusted model. The
adjusted model controlled for age, education, income, BMI, smoking status,
physical activity, history of birth control, cardiac therapeutic usage, diastolic blood
pressure, alcohol consumption, and caffeine consumption.
To address both hypotheses from Aim 2, ordinal logistic regression was
used to assess the relationship between Group 1 and 2 bacteria and headache
disorders. All adjusted models addressing Aim 2 controlled for age, education,
income, BMI, smoking status, physical activity, history of birth control, cardiac
therapeutic usage, diastolic blood pressure, alcohol consumption, and caffeine
consumption. To address first hypothesis in Aim 2, ordinal logistic regression was
implemented to assess the relationship between Group 1 bacteria and headache
disorders. Moderate infection with Group 1 bacteria was not significantly
associated with any level of headache pain. For participants with moderate
infection of Group 1 bacteria, the odds of suffering from mild headache
symptoms were 0.855, 95% CI: 0.649,1.125 in the unadjusted model and 0.844,
95% CI: 0.623,1.144 in the adjusted model. For participants with moderate
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infection of Group 1 bacteria, the odds of suffering from moderate headache
symptoms was 0.875, 95% CI: 0.561,1.366 in the unadjusted model and 0.819,
95% CI: 0.507,1.322 in the adjusted model. Lastly, for participants with moderate
infection of Group 1 bacteria, the odds of suffering from severe headachy
symptoms was 0.819, 95% CI: 0.507,1.322 in the unadjusted model and 0.726,
95% CI: 0.269,1.956 in the adjusted model. Similarly, severe infection with
Group 1 bacteria was insignificantly associated with all levels of headache pain.
For participants with severe infection of Group 1 bacteria, the odds of suffering
from mild headache symptoms was 0.801, 95% CI: 0.499,1.287 in the
unadjusted model and 0.855, 95% CI: 0.527,1.488 in the adjusted model. For
participants with severe infection of Group 1 bacteria, the odds of suffering from
moderate headache symptoms was 0.422, 95% CI: 0.151,1.181 in the
unadjusted model and 0.458, 95% CI: 0.161,1.306 in the adjusted model. For
participants with severe infection of Group 1 bacteria, the odds of suffering from
severe headache symptoms was 0.431, 95% CI: 0.058,3.229 in the unadjusted
model and 0.530, 95% CI: 0.070,4.024 in the adjusted model. None of the Group
1 species were significantly associated with any symptoms suffered from
headaches.
Infection with one Group 2 bacterium was insignificantly associated with
suffering from mild headache symptoms in the unadjusted (unadjusted OR =
0.986, 95% CI: 0.755,1.287) and adjusted models (adjusted OR = 1.016, 95% CI:
0.764,1.352). Conversely, infection with one Group 2 bacterium was significantly
associated with mild headache symptoms in both the unadjusted and adjusted
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models with OR of 1.672, 95% CI: 1.111,2.516 and 1.753, 95% CI: 1.139,2.697,
respectively. Likewise, infection with one Group 2 bacterium was significantly
associated with severe headache symptoms in both unadjusted and adjusted
models with OR of 2.856, 95% CI: 1.281,6.368 and 3.169, 95% CI: 1.310,7.663,
respectively. Infection with two Group 2 bacteria was not significantly associated
with suffering from mild headache symptoms in the unadjusted and adjusted
models with ORs of 0.902, 95% CI: 0.670,1.215 and 0.973, 95% CI: 0.695,1.363,
respectively. However, infection with two Group 2 bacteria was not significantly
associated with suffering from moderate and severe headache symptoms in
crude and adjusted models. Infection with two Group 2 bacteria resulted in OR of
1.051, 95% CI: 0.635,1.740 and 1.168, 95% CI: 0.683,1.998 in the crude and
adjusted models respectively for suffering from moderate headache symptoms.
Infection with two Group 2 bacteria resulted in OR of 1.202, 95% CI: 0.407,3.555
and 1.578, 95% CI: 0.507,4.910 in the crude and adjusted models respectively
for those suffering from severe headache symptoms. No individual species of
Group 2 bacteria was significantly associated with any level of headache
symptoms.
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Table 4.1 Population demographics for WHI OsteoPerio ancillary study
participants for each exposure of interest
Variable

Definition
CDC/AAP Rankings of Periodontal Disease
Two or more interdental sites with
pocket depth (PD)4 mm and two or
No or mild disease
more interdental sites with CAL 3 mm
or having PD5 mm on any tooth.
Two or more interdental sites on
different teeth with CAL4 mm or
Moderate disease
having PD 5 mm on more than one
interdental site on different teeth.
One or more interdental sites with PD5
Severe disease
mm and two or more interdental sites
with CAL6 mm.
Mean CAL Quartiles
Q1
Mean CAL less than or equal to 1.95
Mean CAL greater than 1.95 and less
Q2
than or equal to 2.27
Mean CAL greater than 2.27 and less
Q3
than or equal to 2.66
Q4
Mean CAL greater than 2.66
Group 1 Bacteria
No disease
No Group 1 bacteria
Mild disease
1 or 2 Group 1 bacteria
Moderate Disease
3 or 4 Group 1 bacteria
Severe Disease
5 or 6 Group 1 bacteria
Group 2 Bacteria
No Group 1
No Group 2 bacteria
bacteria present
1 Group 1
1 Group 2 bacteria
bacterium present
2 Group 1 bacteria
2 Group 2 bacteria
present
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n (%)

322 (26.70)

688 (57.05)

196 (16.25)

296 (24.54)
304 (25.21)
302 (25.04)
304 (25.21)
229 (18.99)
621 (51.49)
278 (23.05)
78 (6.47)
610 (50.58)
346 (28.69)
250 (20.73)

Table 4.2. Population categorical characteristics for WHI OsteoPerio ancillary
study participants by CDC/AAP rankings
CDC/AAP Periodontal Disease
Definition
Moderate/
No/Mild
Severe
P value
(n=322)
(n=884)

Total
(n = 1206)
Age at enrollment
<70 years
≥70 years
Total family income
<$50,000
≥$50,000
Education
High School
College
Post-College
BMI
Underweight/
Normal
(< 24.9 kg/m2)
Overweight
(25.0- 29.9 kg/m2)
Obese
(≥30.0 kg/m2)
Cigarette smoking
Never
Former
Current
Birth control usage
Cardiac therapeutic
usage
Bacterial sp., No. (%)
S. sanguis
P. intermedia
T. forsythensis
Capnocytophaga sp.
E. saburreum
C. rectus
P. gingivalis
F. nucleatum

802 (66.50)
402 (33.50)

234 (72.67)
88 (27.33)

568 (64.25)
316 (35.75)

0.0061

756 (62.69)
450 (37.31)

186 (57.76)
136 (42.24)

570 (64.48)
314 (35.52)

0.0329

249 (21.01)
530 (44.73)
406 (34.26)

57 (17.92)
143 (44.97)
118 (37.11)

192 (22.15)
387 (44.64)
288 (33.22)

0.2225

541 (44.86)

137 (42.55)

404 (45.70)

411 (34.08)

113 (35.09)

298 (33.71)

254 (21.06)

72 (22.36)

182 (20.59)

635 (52.65)
531 (44.03)
40 (3.32)
456 (37.81)

190 (59.01)
125 (38.82)
7 (2.17)
126 (39.13)

445 (50.34)
406 (45.93)
33 (3.73)
330 (37.33)

0.5685

29 (2.41)

7 (2.17)

22 (2.49)

0.4564

713 (59.12)
515 (42.70)
453 (37.65)
450 (37.31)
168 (13.93)
202 (16.75)
175 (14.51)
168 (13.93)

187 (58.07)
119 (36.96)
74 (22.98)
112 (34.78)
76 (23.60)
43 (13.35)
25 (7.76)
38 (11.80)

526 (59.50)
396 (44.80)
379 (42.87)
338 (38.24)
320 (36.20)
159 (17.99)
150 (16.97)
130 (14.71)

0.6555
0.0149
<.0001
<.0001
<.0001
0.0567
<.0001
0.1975
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0.6041

0.0202

Table 4.3. Population continuous characteristics for WHI OsteoPerio ancillary
study participants by CDC/AAP rankings
CDC/AAP Periodontal Disease
Definition
Moderate/
No/Mild
Severe
P value
(n=322)
(n=884)

Total
(n = 1206)
Age at
enrollment,
mean±SD, y
Physical activity,
mean±SD, MET
hours per week
Diastolic BP,
mean±SD, mmHg
Caffeine intake,
mean±SD, dietary
caffeine mg
Alcohol intake,
mean±SD,
servings per week

66.47±6.96

65.32±6.87

66.90±6.95

0.5743

14.44±14.31

15.97±16.30

13.89±13.48

0.0270

70.78±8.96

71.03±8.95

70.70±8.96

0.5743

167.86±127.43

156.4±116.5

172.0±131.0

0.0662

2.69±1.75

2.48±4.20

2.76±4.93

0.3746
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Table 4.4. Population categorical characteristics for WHI OsteoPerio ancillary study participants by Mean CAL
quartiles

Q1
(n=296)
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Age at enrollment
<70 years
≥70 years
Total family income
<$50,000
≥$50,000
Education
High School
College
Post-College
BMI
Underweight/
Normal (< 24.9 kg/m2)
Overweight
(25.0- 29.9 kg/m2)
Obese (≥30.0 kg/m2)
Cigarette smoking
Never
Former
Current
Birth control usage
Cardiac therapeutic
usage

Quartiles of Mean CAL
Q2
Q3
(n=304)
(n=302)

Q4
(n=304)

P value

200 (67.57)
96 (32.43)

211 (69.41)
93 (30.59)

207 (68.54)
95 (31.46)

184 (60.53)
120 (39.47)

0.0806

180 (60.81)
116 (39.19)

180 (59.21)
124 (40.79)

187 (61.92)
115 (38.08)

209 (68.75)
95 (31.25)

0.0762

50 (17.24)
126 (43.45)
114 (39.31)

63 (20.93)
135 (44.85)
103 (34.22)

57 (19.32)
136 (46.10)
102 (34.58)

79 (26.42)
133 (44.48)
87 (29.10)

0.0807

124 (41.89)

147 (48.36)

140 (46.36)

130 (42.76)

104 (35.14)

97 (31.91)

111 (36.75)

99 (32.57)

68 (22.97)

60 (19.74)

51 (16.89)

75 (24.67)

178 (60.14)
110 (37.16)
8 (2.70)
104 (35.14)

182 (59.87)
118 (38.82)
4 (1.32)
126 (41.45)

139 (46.03)
155 (51.32)
8 (2.65)
115 (38.08)

136 (44.74)
148 (48.68)
20 (6.58)
111 (36.51)

10 (3.38)

5 (1.65)

5 (1.67)

9 (2.97)

0.2129

<.0001
0.4173
0.3870

Table 4.5 Population continuous characteristics for WHI OsteoPerio ancillary study participants by Mean CAL
quartiles

Q1
(n=296)
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Age at enrollment,
mean±SD, y
Physical activity,
mean±SD, MET hours
per week
Diastolic BP,
mean±SD, mmHg
Caffeine intake,
mean±SD, dietary
caffeine mg
Alcohol intake,
mean±SD, servings
per week

Quartiles of Mean CAL
Q2
Q3
(n=304)
(n=302)

Q4
(n=304)

P value

66.20±6.83

65.91±7.03

66.06±7.10

67.72±6.75

0.0040

16.08±17.01

13.61±12.46

15.33±14.68

12.83±12.56

0.0214

70.35±9.12

71.16±8.68

70.74±8.73

70.87±9.30

0.7444

156.02±111.26

158.46±119.46

183.29±139.53

173.25±135.47

0.0314

2.02±3.55

2.81±4.56

3.01±5.43

2.89±5.14

0.0542

Table 4.6 Population microbial community characteristics for WHI OsteoPerio ancillary study participants by Mean
CAL quartiles

Q1
(n=296)
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Bacterial sp., No. (%)
S. sanguis
P. intermedia
T. forsythensis
Capnocytophaga sp.
E. saburreum
C. rectus
P. gingivalis
F. nucleatum

165 (55.74)
126 (42.57)
81 (27.36)
108 (36.49)
81 (27.36)
41 (13.85)
32 (10.81)
35 (11.82)

Quartiles of Mean CAL
Q2
Q3
(n=304)
(n=302)
173 (56.91)
111 (36.51)
98 (32.24)
97 (31.91)
82 (26.97)
42 (13.82)
33 (10.86)
39 (12.83)

193 (63.91)
132 (43.71)
127 (42.05)
127 (42.05)
112 (37.09)
53 (17.55)
43 (14.24)
43 (14.24)

Q4
(n=304)

P value

182 (59.87)
146 (48.03)
147 (48.36)
118 (38.82)
121 (39.80)
66 (21.71)
67 (22.04)
51 (16.78)

0.1758
0.0383
<.0001
0.0695
0.0005
0.0272
0.0001
0.3234

Table 4.7 Population categorical characteristics for WHI OsteoPerio ancillary
study participants by severity of Group 1 bacterial infection

None/mild
(n=322)
Age at enrollment
<70 years
≥70 years
Total family
income
<$50,000
≥$50,000
Education
High School
College
Post-College
BMI
Underweight/
Normal
(< 24.9 kg/m2)
Overweight
(25.0- 29.9 kg/m2)
Obese
(≥30.0 kg/m2)
Cigarette smoking
Never
Former
Current
Birth control
usage
Cardiac
therapeutic usage
Mean CAL
Q1
Q2
Q3
Q4

Group 1 Bacterial Infection
Moderate
Severe
(n=688)
(n=196)

P value

575 (67.65)
275 (32.35)

181 (65.11)
97 (34.89)

46 (58.97)
32 (41.03)

0.2558

519 (61.06)
331 (38.94)

184 (66.19)
94 (33.81)

53 (67.95)
25 (32.05)

0.1880

172 (20.57)
363 (43.42)
301 (36.00)

57 (20.88)
136 (49.82)
80 (29.30)

20 (26.32)
31 (40.79)
25 (32.89)

0.1991

406 (47.76)

110 (39.57)

25 (32.05)

273 (32.12)

102 (36.69)

36 (46.15)

171 (20.12)

66 (23.74)

17 (21.79)

471 (55.41)
353 (41.53)
26 (3.06)

124 (44.60)
142 (51.08)
12 (4.32)

40 (51.28)
36 (46.15)
2 (2.56)

0.0365

331 (38.94)

102 (36.69)

23 (29.49)

0.2336

17 (2.00)

9 (3.26)

3 (3.85)

0.3458

231 (27.18)
234 (27.53)
201 (23.65)
184 (21.65)

54 (19.42)
56 (20.14)
82 (29.50)
86 (30.94)

11 (14.10)
14 (17.95)
19 (24.36)
34 (43.59)

<.0001
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0.0148

Table 4.8 Population continuous characteristics for WHI OsteoPerio ancillary
study participants by severity of Group 1 bacterial infection

None/mild
(n=322)
Age at
enrollment,
mean±SD, y
Physical
activity,
mean±SD,
MET hours
per week
Diastolic BP,
mean±SD,
mmHg
Caffeine
intake,
mean±SD,
dietary
caffeine mg
Alcohol
intake,
mean±SD,
servings per
week

Group 1 Bacterial Infection
Moderate
Severe
(n=688)
(n=196)

P value

66.26±7.04

66.47±6.81

68.85±6.17

0.069

14.74±14.36

14.08±14.28

12.46±13.83

0.3701

70.76±9.02

70.79±8.81

71.04±8.85

0.9668

162.97±122.44

172.86±129.40

202.32±163.58

0.0265

2.59±4.51

2.96±5.52

2.78±4.19

0.5246
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Table 4.9 Population categorical characteristics for WHI OsteoPerio ancillary
study participants by severity of Group 2 bacterial infection
Group 2 Bacteria
1
2
(n=346)
(n=250)

0
(n=610)
Age at enrollment
<70 years
≥70 years
Total family income
<$50,000
≥$50,000
Education
High School
College
Post-College
BMI
Underweight/
Normal
(< 24.9 kg/m2)
Overweight
(25.0- 29.9 kg/m2)
Obese
(≥30.0 kg/m2)
Cigarette smoking
Never
Former
Current
Birth control usage
Cardiac therapeutic
usage
Mean CAL
Q1
Q2
Q3
Q4

P value

411 (67.38)
199 (32.62)

221 (63.87)
125 (36.13)

170 (68.00)
80 (32.00)

0.4641

383 (62.79)
227 (37.21)

213 (61.56)
133 (38.44)

160 (64.00)
90 (36.00)

0.8292

129 (21.68)
264 (44.37)
202 (33.95)

75 (21.87)
160 (46.65)
108 (31.49)

45 (18.22)
106 (42.91)
96 (38.87)

0.4114

295 (48.36)

148 (42.77)

98 (39.20)

185 (30.33)

121 (34.97)

105 (42.00)

130 (21.31)

77 (22.25)

47 (18.80)

319 (52.30)
266 (43.61)
25 (4.10)
237 (38.85)

180 (52.02)
157 (45.38)
9 (2.60)
125 (36.13)

136 (54.40)
108 (43.20)
6 (2.40)
94 (37.60)

0.7035

12 (1.98)

10 (2.90)

7 (2.80)

0.6081

160 (26.23)
171 (28.03)
143 (23.44)
136 (22.30)

83 (23.99)
87 (25.14)
79 (22.83)
97 (28.03)

53 (21.20)
46 (18.40)
80 (32.00)
71 (28.40)

0.0047
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0.0185

0.6121

Table 4.10 Population continuous characteristics for WHI OsteoPerio ancillary
study participants by severity of Group 2 bacterial infection
Group 2 Bacteria
1
2
(n=346)
(n=250)

0
(n=610)
Age at enrollment,
mean±SD, y
Physical activity,
mean±SD, MET hours
per week
Diastolic BP,
mean±SD, mmHg
Caffeine intake,
mean±SD, dietary
caffeine mg
Alcohol intake,
mean±SD, servings
per week

P value

66.39±6.94

66.60±7.09

66.50±6.84

0.8975

14.73±14.5
9

13.97±13.83

14.40±14.32

0.7372

70.79±8.71

70.92±9.06

70.57±9.42

0.8922

167.33±125
.68

160.68±118.8
4

179.12±142.
10

0.2255

2.74±5.10

2.33±3.87

3.07±4.95

0.1674
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Table 4.11 Unadjusted and adjusted odds of suffering from migraines by exposure status for WHI OsteoPerio
ancillary study participants
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Crude OR (95% CI )
P value Adjusted OR (95% CI)a P value
CDC/AAP Definition of Periodontal Diseaseb
Severe/Moderate Periodontal Disease
0.812 (0.544, 1.213)
0.3097
0.811 (0.530, 1.241)
0.3343
c
Mean CAL
Mean CAL Q2
1.109 (0.673, 1.827)
0.6850
1.071 (0.628, 1.828)
0.8012
Mean CAL Q3
1.746 (1.000, 3.048)
0.0500
1.638 (0.904, 2.966)
0.1038
Mean CAL Q4
1.065 (0.648, 1.749)
0.8035
0.930 (0.546, 1.584)
0.7900
Infection with Group 1 Bacteriad
Moderate Infection
1.622 (0.992, 2.652)
0.0540
1.565 (0.922, 2.658)
0.0973
Severe Infection
1.589 (0.673, 3.754)
0.2907
1.385 (0.547, 3.505)
0.4922
S. sanguis
0.904 (0.620, 1.320)
0.6025
0.927 (0.623, 1.379)
0.7073
P. intermedia
0.960 (0.662, 1.392)
0.8304
0.972 (0.656, 1.439)
0.8856
T. forsythensis
1.414 (0.950, 2.102)
0.0874
1.337 (0.720, 2.481)
0.3579
C. rectus
0.963 (0.592, 1.567)
0.8791
0.968 (0.583, 1.605)
0.8982
P. gingivalis
2.109 (1.082, 4.110)
0.0283
2.252 (1.121, 4.526)
0.0226
F. nucleatum
1.466 (0.806, 2.669)
0.2104
1.337 (0.720, 2.481)
0.3579
Infection with Group 2 Bacteriae
Infection with 1 Group 2 Bacteria
0.821 (0.545, 1.236)
0.3447
0.776 (0.498, 1.207)
0.2599
Infection with 2 Group 2 Bacteria
1.455 (0.852, 2.484)
0.1699
1.363 (0.756, 2.458)
0.3036
Capnocytophaga sp.
1.115 (0.759, 1.637)
0.5803
1.159 (0.773, 1.738)
0.4758
E. saburreum
1.230 (0.822, 1.842)
0.3145
1.303 (0.853, 1.989)
0.2205
a Adjusting for age, education, income, BMI, smoking status, physical activity, history of birth control or cardiac
therapeutic usage, blood pressure, and alcohol and caffeine consumption; b Reference group: No or mild
periodontal disease; c Reference group: Mean CAL Q1; d Reference group: No or mild Group 1 bacterial infection;
e Reference group: 0 Group 2 bacteria present

Table 4.12 Unadjusted and adjusted odds of suffering from mild headache symptoms by exposure status for WHI
OsteoPerio ancillary study participants
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Crude OR (95% CI)
P value
Adjusted OR* (95% CI)
P value
CDC/AAP Definition of Periodontal Diseaseb
Severe/Moderate Periodontal Disease
0.865 (0.699, 1.119)
0.2698
0.758 (0.336, 1.710)
0.5039
c
Mean CAL
Mean CAL Q2
1.015 (0.735, 1.402)
0.9288
0.986 (0.701, 1.387
0.9349
Mean CAL Q3
0.980 (0.708, 1.356)
0.9036
1.040 (0.737, 1.467)
0.8248
Mean CAL Q4
0.818 (0.591, 1.131)
0.2239
0.838 (0.593, 1.185)
0.3186
d
Infection with Group 1 Bacteria
Moderate Infection
0.855 (0.649,1.125)
0.2642
0.844 (0.623,1.144)
0.2751
Severe Infection
0.801 (0.499,1.287)
0.3591
0.855 (0.527,1.488)
0.6448
S. sanguis
1.124 (0.891,1.418)
0.3251
1.104 (0.864,1.410)
0.4282
P. intermedia
0.848 (0.673,1.069)
0.1631
0.831 (0.650,1.061)
0.1380
T. forsythensis
0.915 (0.723,1.158)
0.4606
0.993 (0.772,1.277)
0.9566
C. rectus
0.867 (0.638,1.178)
0.3614
0.814 (0.590,1.122)
0.7975
P. gingivalis
0.791 (0.570,1.096)
0.1591
0.850 (0.602,1.198)
0.3527
F. nucleatum
0.913 (0.656,1.272)
0.5921
1.028 (0.723,1.463)
0.8758
e
Infection with Group 2 Bacteria
Infection with 1 Group 2 Bacteria
0.986 (0.755,1.287)
0.9161
1.016 (0.764,1.352)
0.9109
Infection with 2 Group 2 Bacteria
0.902 (0.670,1.215)
0.4983
0.973 (0.695,1.363)
0.8752
Capnocytophaga sp.
0.902 (0.712,1.142)
0.3908
0.907 (0.708,1.163)
0.4426
E. saburreum
0.979 (0.768,1.248)
0.8628
0.977 (0.756,1.261)
0.8569
a Adjusting for age, education, income, BMI, smoking status, physical activity, history of birth control or cardiac
therapeutic usage, blood pressure, and alcohol and caffeine consumption; b Reference group: No or mild periodontal
disease; c Reference group: Mean CAL Q1; d Reference group: No or mild Group 1 bacterial infection; e Reference
group: 0 Group 2 bacteria present

Table 4.13 Unadjusted and adjusted odds of suffering from moderate headache symptoms by exposure status for
WHI OsteoPerio ancillary study participants
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Crude OR (95% CI)
P value
Adjusted OR* (95% CI) P value
b
CDC/AAP Definition of Periodontal Disease
Severe/Moderate Periodontal Disease
0.737 (0.497,1 .091)
0.1276
0.728 (0.483, 1.098)
0.1299
c
Mean CAL
Mean CAL Q2
0.699 (0.402, 1.112)
0.1207
0.614 (0.356, 1.059)
0.0797
Mean CAL Q3
0.687 (0.413, 1.141)
0.1471
0.728 (0.427, 1.239)
0.2417
Mean CAL Q4
0.726 (0.440, 1.196)
0.2085
0.806 (0.479, 1.355)
0.4148
d
Infection with Group 1 Bacteria
Moderate Infection
0.875 (0.561, 1.366)
0.5579
0.819 (0.507, 1.322)
0.4138
Severe Infection
0.422 (0.151, 1.181)
0.1004
0.458 (0.161, 1.306)
0.1442
S. sanguis
1.138 (0.781, 1.657)
0.5018
1.092 (0.739, 1.615)
0.6589
P. intermedia
0.907 (0.625, 1.316)
0.6072
0.845 (0.571, 1.251)
0.4008
T. forsythensis
0.747 (0.506, 1.105)
0.1441
0.817 (0.543, 1.231)
0.3344
C. rectus
0.837 (0.501, 1.397)
0.4957
0.751 (0.436, 1.293)
0.3019
P. gingivalis
0.694 (0.389, 1.240)
0.2171
0.764 (0.424, 1.380)
0.3725
F. nucleatum
1.006 (0.594, 1.706)
0.9814
1.114 (0.643, 1.928)
0.7007
Infection with Group 2 Bacteriae
Infection with 1 Group 2 Bacteria
1.672 (1.111, 2.516)
0.0137
1.753 (1.139, 2.697)
0.0108
Infection with 2 Group 2 Bacteria
1.051 (0.635, 1.740)
0.8473
1.168 (0.683, 1.998)
0.5697
Capnocytophaga sp.
1.217 (0.840, 1.765)
0.2997
1.229 (0.833, 3.409)
0.2986
E. saburreum
1.052 (0.715, 1.547)
0.7980
1.090 (0.730, 1.628)
0.6732
a Adjusting for age, education, income, BMI, smoking status, physical activity, history of birth control or cardiac
therapeutic usage, blood pressure, and alcohol and caffeine consumption; b Reference group: No or mild periodontal
disease; c Reference group: Mean CAL Q1; d Reference group: No or mild Group 1 bacterial infection; e Reference
group: 0 Group 2 bacteria present

Table 4.14 Unadjusted and adjusted odds of suffering from severe headache symptoms by exposure status for WHI
OsteoPerio ancillary study participants
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Crude OR (95% CI)
P value
Adjusted OR* (95% CI) P value
CDC/AAP Definition of Periodontal Diseaseb
Severe/Moderate Periodontal Disease
0.768 (0.358,1.650)
0.4988
0.758 (0.336,1.710)
0.5039
Mean CALc
Mean CAL Q2
0.518 (0.189,1.419)
0.2005
0.510 (0.168,1.544)
0.2334
Mean CAL Q3
0.687 (0.413,1.141)
0.1471
0.535 (0.176,1.622)
0.2688
Mean CAL Q4
0.700 (0.277,1.765)
0.4494
0.858 (0.325,2.265)
0.3186
d
Infection with Group 1 Bacteria
Moderate Infection
0.608 (0.231,1.605)
0.3152
0.726 (0.269,1.956)
0.5265
Severe Infection
0.431 (0.058,3.229)
0.4131
0.530 (0.070,4.024)
0.5389
S. sanguis
0.727 (0.356,1.484)
0.3810
0.641 (0.298,1.380)
0.2559
P. intermedia
0.741 (0.352,1.560)
0.4299
0.783 (0.354,1.730)
0.5451
T. forsythensis
0.670 (0.306,1.468)
0.3170
0.871 (0.387,1.964)
0.7399
C. rectus
1.190 (0.482,2.940)
0.7061
1.361 (0.540,3.427)
0.5135
P. gingivalis
0.626 (0.188,2.083)
0.4454
0.745 (0.221,2.512)
0.6353
F. nucleatum
0.917 (0.317,2.654)
0.8726
1.152 (0.392,3.385)
0.7975
e
Infection with Group 2 Bacteria
Infection with 1 Group 2 Bacteria
2.856 (1.281,6.368)
0.0103
3.169 (1.310,7.663)
0.0105
Infection with 2 Group 2 Bacteria
1.202 (0.407,3.555)
0.7388
1.578 (0.507,4.910)
0.4312
Capnocytophaga sp.
1.570 (0.768,3.207)
0.2161
1.583 (0.735,3.409)
0.2403
E. saburreum
1.114 (0.529,2.350)
0.7758
1.337 (0.613,2.918)
0.4659
a Adjusting for age, education, income, BMI, smoking status, physical activity, history of birth control or cardiac
therapeutic usage, blood pressure, and alcohol and caffeine consumption; b Reference group: No or mild periodontal
disease; c Reference group: Mean CAL Q1; d Reference group: No or mild Group 1 bacterial infection; e Reference
group: 0 Group 2 bacteria present

CHAPTER 5
CONCLUSIONS

5.1 Discussion:
5.1.1 Migraines
Periodontal disease, as defined by the CDC/AAP and by quartiles of mean
CAL, was not significantly associated with migraines among older, predominantly
white women in the US. The Fifth European Workshop on Periodontology,
hosted in 2005, used CAL as the sole marker of periodontitis in epidemiologic
studies of risk factors. In 2007, the CDC/AAP proposed the first draft of the
rankings used to address the first hypothesis of Aim 1. The current rankings
included cases definitions for three instead of two rankings. Since then, the
rankings set by the CDC/AAP have been used in numerous epidemiological
studies (Page & Eke, 2007; Penoni, Torres, Farias, & Fernandes, 2016) and it
has even been suggested that these rankings could be standardized for all future
population-based studies of periodontal disease (Page & Eke, 2007).
However, these definitions are based on measurements of periodontal
destruction (PD and CAL), which capture the damage caused by inflammation
and are not indicative of a current inflammatory response. Furthermore, both PD
and CAL may lead to misclassification as using PD might result in pseudo-pocket
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to be considered true and using CAL may similarly cause sites of gingival
recession by mechanical forces to be considered true symptoms of periodontal
disease (Pei, He, & Ouyang, 2012). Because we are suggesting that the
inflammatory responses related to a current periodontal infection are related to
migraines, the association would likely be underestimated by these exposure
measures as they can lead to an overestimation of periodontal disease presence.
Conversely, using PD and CAL as measures of periodontal disease can also
lead to an underestimation of periodontal disease prevalence, as both measures
only consider the interproximal sites of teeth and periodontal disease can also
occur at buccal and lingual sites. To combat these issues, Pei and colleagues
proposed a three-level definition of periodontal disease that uses PD, CAL, and
additionally measure, bleeding on probing (BOP), to define the severity of
disease where all six sites per tooth were considered (Pei et al., 2012). A positive
BOP would be indicative of a current infection and its subsequent inflammatory
responses. Future investigations into the relationship between periodontal
disease and migraines would benefit from using this definition of periodontal
disease. Because of this potential misclassification bias, our study may have
failed to detect meaningful differences between those with and without
periodontal disease. Future investigations into the relationship between
periodontal disease and migraines should consider a more inclusive definition
that accounts for inflammation.
Peskersoy and colleagues reported findings from their investigation into
the relationship between migraines and oral comorbidities. They found that
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participants with migraines reported more frequently tooth wear and abrasion.
Furthermore, they found that two additional measures of oral health, DMFT and
plaque index scores were significantly associated with migraines. While this is
evidence of a relationship between oral health and migraines, this study did not
use any of the measures or definitions of periodontal disease used in this study,
making comparisons between their study and ours impossible.
Participants with Group 1 bacteria present reported migraine more
frequently (Moderate infection adjusted OR = 1.565, 95% CI: 0.922, 2.658;
severe infection adjusted OR = 1.385, 95% CI: 0.547, 3.505), even though this
did not reach statistical significance. However, the presence of P. gingivalis was
positively associated with migraines (adjusted OR = 2.252, 95% CI: 1.121,
4.526). As a prominent member of the oral microbiome and the demonstrated
ability to colonize the oral epithelial, P. gingivalis is considered a keystone
species in periodontal disease as a member of the “red complex” identified by
Haffajee and colleagues, which has been strongly implicated in periodontal
disease (Haffajee, Socransky, Patel, & Song, 2008). As part of the immune
response to periodontal disease, the immune system produces the antimicrobial
agent, NO. The lipid A-associated proteins of the P. gingivalis LPS (PgLPS) has
been shown to induce nitric oxide production in clinical studies (E. Y. Choi et al.,
2007; Herath et al., 2016) and is considered a crucial virulence factor in
periodontal pathogenesis. Our study provides evidence of a significant, positive
association between a bacterial species, P. gingivalis, and migraines.
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Gonzalez and colleagues, in a collaboration with Knight labs, were the first
to suggest a relationship between oral bacteria and migraines (Gonzalez et al.,
2016). They reported significant increases in nitrate, nitrite, and nitric oxide
reductase genes in oral samples collected from those who suffer from migraines.
After claiming they had evidence of a potential link between oral microbes and
migraines, the results of this study were sensationalized by numerous national
news sources. A criticism of this study was that the authors implied that they
directly measured genes of interests related to reducing nitrates and nitrites.
However, their predictions were based on prior projects, and did not directly
demonstrate link between periodontal bacteria, nitric oxide production, and
migraines. Additionally, none of their methods or results suggested any
consideration for important confounders. Infection with Group 2 bacteria was not
associated with migraines.
5.1.2 Headache Disorders
Periodontal disease, defined two ways, was not associated with headache
disorders. Furthermore, headaches were not related to the presence of Group 1
bacteria. We hypothesized that the presence of NO producing oral bacteria
(Group 1) would be positively associated with migraines. As headaches have
many different causes, the association of Group 1 bacteria and headaches would
not have expected to be strong. Without differentiating the type of headache
disorder, it is impossible to limit our exposure population to only those headache
disorders linking to NO.
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Contradictory to our second hypothesis of Aim 2, Group 2 bacteria were
positively associated with headache disorders. Infection with a Group 2
bacterium was significantly associated with moderate and severe headache
symptoms (Moderate symptom adjusted OR = 1.753; 95% CI: 1.139,2.697;
Severe symptom adjusted OR = 3.169, 95% CI: 1.310,7.663); however, no
individual species of Group 2 bacteria was associated with migraines.
As periodontal disease and its associated bacterial pathogens have been
shown to induce NO production by the immune system (Eun Young Choi et al.,
2011; Kim, Ha, Choi, Choi, & Choi, 2004; Pelt, Zimmermann, Ulbrich, &
Bernimoulin, 2002; Skaleric, Gaspirc, McCartney-Francis, Masera, & Wahl, 2006;
Hussain, Mckay, Gonzales-Marin, & Allaker, 2015; E. Y. Choi et al., 2007; Herath
et al., 2016; Kato, Mikami, & Saito, 2001; Velsko et al., 2015; Chukkapalli et al.,
2015; English, Patrick, Orlicek, McCordic, & Shenep, 1996; Jian Jun Gao, Xue,
Zuvanich, Haghi, & Morrison, 2001; Kendall, Haase, Li, Xiao, & Bartold, 2000;
Hirose et al. 2001), and NO has been implicated in the pathophysiology of
headache disorders (D’andrea et al., 1994; Gruber et al., 2010; Olesen, 2008;
Sarchielli et al., 1996; Shimomura et al., 1999), it is biologically feasible that
periodontal disease and its associated bacterial pathogens to be positively
associated with headache disorders.
Additionally, it is important to note, that estrogen has been shown to be
protective against periodontal disease (Brasil et al., 2017; Nebel, 2012), but is
associated with headache disorders, and migraines in particular (Chai, Peterlin,
& Calhoun, 2014). Estrogen plays an important role in regulating inflammatory
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responses to infection, specifically the production of NO (Brasil et al., 2017;
Nevzati et al., 2015; Townsend, Meuchel, Thompson, Pabelick, & Prakash,
2011). Estrogen receptors (ER), ERα and ERβ are expressed in smooth muscle
cells, macrophages, and endothelial cells, and activation of ERα in endothelial
cells has shown to increase the expression of NO synthase (eNOS) in the
presence of estrogen (17β-estradiol) (Furchgott, 1999; Mendelsohn, 2000; Chen
et al., 1999). Furthermore, mutations in the ERα gene have been associated with
increased risk of periodontal disease (Weng et al., 2015). The ability of ERs to
increase NO production in the presence of estrogen could explain the increased
prevalence of headache disorders in women (Chai et al., 2014)
Findings from our investigation into the relationship between periodontal
disease and the subsequent production of NO due to its related pathogenic
bacteria and headache disorders provides some evidence of the association
between our exposures of interest and migraines but not between our general
headache disorder variable. Further investigations into the periodontal disease
and headache disorders is warranted.
5.2 Strengths:
This study has several strengths. First, the WHI ancillary OsteoPerio study
had information on all important, potential confounders in the relationship
between periodontal disease and its ensuing inflammatory responses and
headache disorders. This allowed for statistical control of potential confounders.
Second, the variables from the OsteoPerio study were carefully chosen,
collected, and measured. Third, a biologically plausible hypothesis linking NO
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producing oral bacteria and migraines was tested. Lastly, my study these findings
contribute to an understudied area on headache etiology.
5.3 Limitations:
First, self-reported headache is vulnerable to misclassification bias. A
recent validation study found high concordance between self-reported
questionnaire data and medical records (κ=.61 for chronic conditions),
suggesting our study would only minimally be influenced by misclassification bias
(Van Gelder et al., 2015). Second, the bacterial species were classified as
present or absent with no quantification limiting the statistical analyses at our
disposal. Third, the results of our study are not generalizable to the entire United
States population, but to older women aged 53 to 83. These results need to be
replicated in other populations.
Last, this study used a cross-sectional design and therefore temporality
cannot be assessed. This is particularly problematic since headache disorders
are more prevalent amongst younger individuals (Younger, 2016), and
conversely periodontal disease, as defined by periodontal destruction, is typically
more prevalent in older populations and includes past and current infection
(Leite, Peres, Do, Demarco, & Peres, 2017; Page & Eke, 2007). However, the
proposed biological plausibility explains this perceived paradox. NO produced by
the immune system in response periodontal disease causes the vasodilation
responsible for the pain suffered from headache disorders. It is well established
that the immune system declines with age, including the production of NO
(Kissin, Tomasi, McCartney-Francis, Gibbs, & Smith, 1997; Liang, Domon,
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Hosur, Wang, & Hajishengallis, 2009). If our hypotheses are correct, the aging
body’s declining ability to illicit an immune response, specifically the production of
NO, not only explains the body’s decreased ability to fight the infections
associated with periodontal disease, but also explains the decrease headache
disorder prevalence in older populations. Furthermore, results from the National
Health and Nutrition Examination Survey (NHANES) 2009-2012 suggests that
almost half of adults age 30 years and older have periodontal disease with
severe periodontal disease affecting 8.9% of the population (Eke et al., 2015).
Moreover, NHANES III data suggest 90% of persons aged 20-79 needed
periodontal treatment with increasing complexity of periodontal treatments with
age (Dye & Vargas, 2002). While periodontal disease is associated with older
age, children and adolescence also suffer (Merchant et al., 2015).
5.4 Importance:
Headaches are the 6th leading cause of disability globally. Approximately
46% of the adult population suffers from headaches, 42% suffer from tensiontype headaches, 11% suffer from migraines, and 3% suffer from chronic daily
headaches (Stovner et al., 2007). Considering the disability induced by headache
disorders, further investigation into their cause is warranted. The literature on the
association between periodontal disease and headache disorders is limited, even
though it is biologically plausible. Our study provides epidemiological data on the
association between periodontal disease and headache disorders.
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5.5 Conclusions:
P. gingivalis presence is positively associated with migraines among older
white women after controlling for potential confounders. Further investigation into
measures of oral health, oral microbes, and NO in relation to headache disorders
is warranted.
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